Benitec Biopharma Inc. · NASDAQ:BNTC

Benitec Biopharma — Investor Presentation (November 2012)

26 slides from Benitec Biopharma's investor presentation, November 2012

  1. Slide 1: Corporate Presentation

    Corporate Presentation November 2012

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presenta,on contains forward looking statements that involve risks and uncertain,es. Although we believe that the expecta,ons reflected in the forward looking statements are reasonable at this ,me, Benitec Biopharma can give no assurance that these expecta,ons will pro

  3. Slide 3: Overview

    Overview  Developing therapeu0cs based on gene silencing technology  Located in Sydney, AU (ASX: BLT)  Pipeline of in-­‐house and partnered programs  Dominant IP posiIon in RNAi (ddRNAi)  Proprietary, inherent value of ddRNAi  “Silences” disease causing genes by delivering short hairpin RNA (s

  4. Slide 4: Pipeline

    Pipeline Indica0on Partners/ Collaborators Discovery Pre-­‐clinical Clinical HIV/AIDS Calimmune HepaIIs C Benitec/Tacere University of New South Drug resistant lung cancer Wales Cancer-­‐associated Stanford University neuropathic pain HepaIIs B Biomics Biotechnologies Oculopharyngeal muscular Royal

  5. Slide 5: ddRNAi Profile

    ddRNAi Profile

  6. Slide 6: Gene Silencing Approaches: ddRNAi versus siRNA

    Gene Silencing Approaches: ddRNAi versus siRNA 6

  7. Slide 7: Two Approaches for RNAi-Mediated Gene Silencing

    Two Approaches for RNAi- Mediated Gene Silencing ddRNAi (including shRNA): shRNA siRNA siRNA: Produced intracellularly from expression Pre-synthesized & delivered constructs Can interact with TLRs resulting in Expressed within nucleus, shRNA do not interferon responses. Potentially can be interact w

  8. Slide 8: ddRNAi Competitive Advantages

    ddRNAi Competitive Advantages  ddRNAi can poten0ally target over 22,000 genes across mul0ple indica0ons including cancer, neurological disease, infec0ous disease, autoimmune disease, and gene0c disease  Can design therapeu0cs simply on the basis of sequence rather than laborious, expensive and 0me

  9. Slide 9: Established IP Position

    Established IP Position  Exclusive worldwide irrevocable license from CSIRO to develop and commercialize all human applica0ons of expressed RNAi (or DNA-­‐directed RNA interference (ddRNAi)) technology  No royalty obliga0ons to CSIRO (CSIRO is a shareholder)  Around 100 filed and issued patents, w

  10. Slide 10: Patent Estate History

    Patent Estate History  Former management ini0ated li0ga0on in mid 2000s against Nucleonics in defense of Graham family of patents and, as a result, were required to defend them in re-­‐examina0ons in all major jurisdic0ons  Benitec prevailed in all patent nego0a0ons with its patents re-­‐examined

  11. Slide 11: Bi-Modal Growth Strategy

    Bi-Modal Growth Strategy ddRNAi technology Human therapeu0cs Research tools Immediate opportuniIes to leverage Exploit pladorm as a research tool through potenIal for wide range of therapeuIcs technology licensing Long-­‐term value by developing own pipeline and licensing drugs to pharma aTer Deals

  12. Slide 12: Program Overview

    Program Overview

  13. Slide 13: Lead In-house Program – HCV (TT034)

    Lead In-house Program – HCV (TT034)  Benitec Approach:  A “one shot monotherapy cure,” intended to clear HCV with a single injecIon • TT-­‐034 was a high priority program at Pfizer • TT-­‐034 is ready to enter a first in man phase I/IIa study subject to final regulatory approval in 2013  All require

  14. Slide 14: TT034 Program Status

    TT034 Program Status  Significant investment by Pfizer to bring TT034 to clinical trials. Reverted to Tacere when Pfizer closed Sandwich facility in UK  First in man Phase I/IIa clinical trial to be conducted in 2013 in US HCV pa0ents  All safety and toxicology studies have been completed  Pre-­‐IN

  15. Slide 15: Cancer-Associated Neuropathic Pain

    Cancer-Associated Neuropathic Pain  Quality of life for pa0ents in end stage disease becomes progressively worse as the need for increasing doses of opiates such as morphine  Global market for cancer associated pain -­‐ $2 Billion  Benitec Approach:  Developing a ddRNAi therapeuIc that silences

  16. Slide 16: Drug Resistant Lung Cancer

    Drug Resistant Lung Cancer  Lung cancer is the most common cause of cancer death  Only 15% of pa0ents survive more than 5 years  Resistance to chemotherapy is common  Benitec Approach:  Developing a treatment for chemotherapy drug-­‐resistant non-­‐small cell lung cancer (NSCLC)  Silencing the

  17. Slide 17: HBV

    HBV  2 Billion people infected with Hepa00s B and 350M are chronic carriers worldwide  In U.S. over 1.25M chronic ac0ve pa0ents and over 60,000 new cases/year  Although there is a prophylac0c vaccine, there are no current treatments available for acute HBV infec0on  Complete elimina0on of virus

  18. Slide 18: Oculopharyngeal Muscular Dystrophy

    Oculopharyngeal Muscular Dystrophy  Rare orphan disease causing muscle was0ng  Ojen fatal with no current disease treatment  A mutant form of gene called Poly (A) Binding Protein Nuclear 1 (PABPN1) is associated with the disease  Benitec Approach:  Develop a DNA construct that both silences the

  19. Slide 19: Further Potential Applications of ddRNAi

    Further Potential Applications of ddRNAi  Other infec0ous diseases  Mul0ple cancer types  Cardiovascular disease  Hun0ngton’s disease  Alzheimer’s Hepbarna™  Autoimmune Pabparna™  Stem cells  Gene0c diseases 19

  20. Slide 20: Corporate Profile

    Corporate Profile

  21. Slide 21: Management Team

    Management Team  Peter French, MBA, PhD: Chief Execu0ve Officer Joined Benitec in 2009 as Chief ScienIfic Officer before being appointed CEO in 2010. Previously Founder and Director Cryosite (ASX:CTE), a stem cell storage company. Also served as CEO of Probiomics Ltd. where he led the commercial efforts

  22. Slide 22: Board of Directors

    Board of Directors  Peter Francis (Chairman) A partner at Francis Abourizk Lightowlers (FAL), a firm of commercial and technology lawyers with offices in Melbourne, Australia.  Dr. Mel Bridges (Non-­‐Execu0ve Director) Chairman of Alchemia Ltd and GeneIc Technologies Ltd. He also co-­‐founded listed

  23. Slide 23: Financial Information

    Financial Information Share price at 30 September AUD $0.016 per share Market capitalisaIon AUD$ 15.5 million  Share price movements Issued equity: ordinary shares 970,628,529 OpIons on issue 424,785,202 Cash balance at 31 December 2011 AUD$ 3.1 million OperaIonal monthly burn rate for the six mont

  24. Slide 24: HCV Program – 2013 Milestones

    HCV Program – 2013 Milestones • RAC approval • IND • Clinical trial commencement • Interim data review 24

  25. Slide 25: Opportunity Summary

    Opportunity Summary  Potent long-­‐las0ng gene silencing plamorm technology in ddRNAi  Robust market poten0al with over 22,000 human genes and genes from disease-­‐causing organisms  Dominant global posi0on with IP now secure  Broad pipeline in mul0ple high value therapeu0c areas  Clinical safe

  26. Slide 26: Contact Information

    Contact Information Carl Stubbings Peter French Chief Business Officer Chief Execu0ve Officer m: +61 (0)423666374 m: +61 (0)412457595 e: cstubbings@benitec.com e: pfrench@benitec.com 26

Benitec Biopharma — Investor Presentation (November 2012) on 6ix